Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments.

"Disclosure Dr Anderley Gordon discloses no conflicts of interest in this work. Dr Edwina Johnston discloses no conflicts of interest in this work. Dr David K Lau discloses he is the recipient of the Australasian Gastro-Intestinal Trials Group/Merck Clinical Research Fellowship. Dr Naureen Starlings disclosures include the following: Research Funding: AstraZeneca, BMS, Pfizer, NIHR EME, RMCC, RM/ICR BRC Travel & Accommodation: AstraZeneca, BMS, Eli Lilly, Merck, Roche, MSD Oncology (02/2019 GI ASCO flights and accommodation) Honoraria: Eli Lilly, Merck Serono, MSD Oncology, Pierre Fabre, Servier, GSK, Amgen Advisory Board: Pfizer, AstraZeneca, Servier, MSD (Merck) The authors report no other conflicts of interest in this work."

"The authors are supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London. Disclosure: Dr Anderley Gordon discloses no conflicts of interest in this work.: Dr Edwina Johnston discloses no conflicts of interest in this work.: Dr David K Lau discloses he is the recipient of the Australasian Gastro-Intestinal Trials Group/Merck Clinical Research Fellowship.: Dr Naureen Starlings disclosures include the following:: Research Funding: AstraZeneca, BMS, Pfizer, NIHR EME, RMCC, RM/ICR BRC: Travel & Accommodation: AstraZeneca, BMS, Eli Lilly, Merck, Roche, MSD Oncology (02/2019 GI ASCO flights and accommodation): Honoraria: Eli Lilly, Merck Serono, MSD Oncology, Pierre Fabre, Servier, GSK, Amgen: Advisory Board: Pfizer, AstraZeneca, Servier, MSD (Merck): The authors report no other conflicts of interest in this work."